Brokerages expect that Itamar Medical Ltd. (NASDAQ:ITMR) will announce sales of $11.10 million for the current quarter, Zacks reports. Three analysts have issued estimates for Itamar Medical’s earnings, with estimates ranging from $10.40 million to $12.30 million. Itamar Medical posted sales of $8.38 million during the same quarter last year, which would indicate a positive year over year growth rate of 32.5%. The company is scheduled to report its next earnings report on Wednesday, May 26th.

On average, analysts expect that Itamar Medical will report full year sales of $52.70 million for the current financial year, with estimates ranging from $52.48 million to $53.30 million. For the next fiscal year, analysts expect that the business will report sales of $68.86 million, with estimates ranging from $63.55 million to $74.60 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that follow Itamar Medical.

Several equities research analysts have weighed in on ITMR shares. Zacks Investment Research cut Itamar Medical from a “hold” rating to a “sell” rating in a report on Friday, March 5th. Piper Sandler increased their price objective on Itamar Medical from $26.00 to $30.00 and gave the company an “overweight” rating in a report on Tuesday, March 2nd. Finally, HC Wainwright increased their price objective on Itamar Medical from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, March 15th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $29.83.

Shares of NASDAQ ITMR traded down $0.19 during trading hours on Monday, hitting $24.05. 2 shares of the company traded hands, compared to its average volume of 41,669. The stock has a market capitalization of $387.40 million, a price-to-earnings ratio of -36.18 and a beta of 1.26. The company’s 50 day moving average price is $23.73 and its 200 day moving average price is $21.87. Itamar Medical has a 12 month low of $12.68 and a 12 month high of $29.00.

A number of institutional investors have recently bought and sold shares of ITMR. Perkins Capital Management Inc. grew its holdings in Itamar Medical by 5.0% during the fourth quarter. Perkins Capital Management Inc. now owns 21,000 shares of the company’s stock worth $417,000 after acquiring an additional 1,000 shares during the period. Jane Street Group LLC acquired a new stake in Itamar Medical during the fourth quarter worth about $926,000. Finally, Schonfeld Strategic Advisors LLC grew its holdings in Itamar Medical by 137.0% during the third quarter. Schonfeld Strategic Advisors LLC now owns 50,392 shares of the company’s stock worth $1,029,000 after acquiring an additional 29,132 shares during the period. 29.42% of the stock is currently owned by hedge funds and other institutional investors.

Itamar Medical Company Profile

Itamar Medical Ltd. engages in the research, development, marketing, sale, and leasing of non-invasive medical devices for the cardiology market. The company offers medical devices based on Peripheral Arterial Tone (PAT) signal, which measures changes in the patient's peripheral arterial pulse volumes and various parameters of arterial activities.

Read More: Holder of Record

Get a free copy of the Zacks research report on Itamar Medical (ITMR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Itamar Medical (NASDAQ:ITMR)

Receive News & Ratings for Itamar Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Itamar Medical and related companies with MarketBeat.com's FREE daily email newsletter.